Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
For more information, contact our Adult Leukemia Program.
For more information, contact our Adult Lymphoma Program.
For more information, contact our Multiple Myeloma Program.
Glenn Hanna, MD, describes the trial of CTLA-4 inhibition in combination with memory-like natural killer (NK) cell immune cell therapy in advanced head and neck cancer.
New Patient Appointments